Have a feature idea you'd love to see implemented?
Let us know!
ACAD Acadia Pharmaceuticals Inc
Price (delayed)
$15
Market cap
$2.49B
P/E Ratio
83.33
Dividend/share
N/A
EPS
$0.18
Enterprise value
$2.35B
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who
Highlights
The net income has surged by 128% year-on-year
The EPS has soared by 126% YoY
The quick ratio has declined by 27% year-on-year but it is up by 5% since the previous quarter
The gross margin has declined by 6% year-on-year
Key stats
What are the main financial stats of ACAD
Market
Valuations
Earnings
Shares outstanding
165.88M
Market cap
$2.49B
Enterprise value
$2.35B
Price to earnings (P/E)
83.33
Price to book (P/B)
4.8
Price to sales (P/S)
2.79
EV/EBIT
51.43
EV/EBITDA
41.12
EV/Sales
2.64
Revenue
$890.53M
EBIT
$45.74M
EBITDA
$57.2M
Free cash flow
$80.48M
Per share
Balance sheet
Liquidity
EPS
$0.18
Free cash flow per share
$0.49
Book value per share
$3.13
Revenue per share
$5.38
TBVPS
$4.87
Total assets
$914.1M
Total liabilities
$397.4M
Debt
$47.19M
Equity
$516.7M
Working capital
$391.07M
Debt to equity
0.09
Current ratio
2.16
Quick ratio
1.83
Net debt/EBITDA
-2.37
Margins
Efficiency
Dividend
EBITDA margin
6.4%
Gross margin
91.7%
Net margin
3.4%
Operating margin
2.6%
Return on assets
3.9%
Return on equity
6.9%
Return on invested capital
15.7%
Return on capital employed
7.9%
Return on sales
5.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACAD stock price
How has the Acadia Pharmaceuticals stock price performed over time
Intraday
1.76%
1 week
4.97%
1 month
-2.47%
1 year
-32.52%
YTD
-52.09%
QTD
-2.47%
Financial performance
How have Acadia Pharmaceuticals's revenue and profit performed over time
Revenue
$890.53M
Gross profit
$816.84M
Operating income
$22.82M
Net income
$30.57M
Gross margin
91.7%
Net margin
3.4%
The net income has surged by 128% year-on-year
The operating income has soared by 118% YoY
The net margin has soared by 117% YoY
The operating margin has soared by 111% YoY
Growth
What is Acadia Pharmaceuticals's growth rate over time
Valuation
What is Acadia Pharmaceuticals stock price valuation
P/E
83.33
P/B
4.8
P/S
2.79
EV/EBIT
51.43
EV/EBITDA
41.12
EV/Sales
2.64
The EPS has soared by 126% YoY
ACAD's price to book (P/B) is 43% lower than its 5-year quarterly average of 8.3 and 43% lower than its last 4 quarters average of 8.3
The company's equity rose by 31% YoY and by 11% QoQ
ACAD's P/S is 71% below its 5-year quarterly average of 9.3 and 43% below its last 4 quarters average of 4.8
ACAD's revenue has soared by 62% YoY and by 9% QoQ
Efficiency
How efficient is Acadia Pharmaceuticals business performance
The ROS has soared by 183% QoQ and by 127% YoY
ACAD's return on invested capital has surged by 145% year-on-year
The ROE has soared by 125% YoY
Acadia Pharmaceuticals's return on assets has surged by 122% YoY
Dividends
What is ACAD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACAD.
Financial health
How did Acadia Pharmaceuticals financials performed over time
The total assets is 130% more than the total liabilities
The total liabilities has soared by 61% YoY
The total assets has grown by 42% YoY and by 7% from the previous quarter
The debt is 91% lower than the equity
The company's equity rose by 31% YoY and by 11% QoQ
The debt to equity has declined by 31% year-on-year and by 18% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.